Australia
· Delayed Price · Currency is AUD Neurotech International Company Description
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia.
The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity.
It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Anthony Filippis |
Contact Details
Address: 55 Collins Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9498 3130 |
| Website | neurotechinternational.com |
Stock Details
| Ticker Symbol | NTI |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000NTI9 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Peter James Lawrence Griffiths B.Sc. | Chief Executive Officer of AAT Research Ltd |
| Dr. Anthony Filippis M.B.A., Ph.D. | MD, Chief Executive Officer and Director |
| Gerald Quigley | Director of Public Relations and Director |
| Associate Prof. Carolyn Ellaway | Chief Medical Officer |
| Dr. Bonni Goldstein M.D. | Chief Medical Advisor for USA |
| Alessandra Marie Gauvin | Company Secretary |